Novel means and methods for the treatment of hearing loss and phantom hearing
AssigneeUniversity of Geneva
InventorsKarl-Heinz Krause, Botond Banfi
Life of this patent
Estimating the term…
Loading patent…
AssigneeUniversity of Geneva
InventorsKarl-Heinz Krause, Botond Banfi
Estimating the term…
This invention relates to modulators of NADPH oxidase as a medicament for the treatment and/or prevention of hearing loss and/or phantom hearing. Such modulators preferably act by inhibiting NADPH oxidase activity, wherein the NADPH oxidase comprises or consists of the amino acid sequence of any one of SEQ ID NO: 1, 3 or 5, or (ii) is encoded by a nucleic acid comprising or consisting of the sequence of any one of SEQ ID NO: 2, 4, 6, 23 or 24, or (iii) is a fragment of the protein according to (i) or (ii) and exhibits NADPH oxidase activity, or (iv) has a sequence at least 75% identical with the protein according to (i) or (ii) or with the fragment according to (iii) and exhibits NADPH oxidase activity. Also provided are pharmaceutical compositions, medical uses and diagnostic uses of compounds of the invention.
-40. (canceled)
A method for reducing the expression of NOX3 in the inner ear of a subject comprising administering an effective amount of a siRNA inhibitor of NOX3, or of a pharmaceutical composition comprising an effective amount of a siRNA inhibitor of NOX3, to the subject, wherein NOX3 protein comprises or consists of the amino acid sequence of any one of SEQ ID NO:
A method for reducing the formation (generation/production) of reactive oxygen species (ROS) in the inner ear of a subject comprising administering to the subject an effective amount of a siRNA inhibitor of NOX3 or of a pharmaceutical composition comprising [an effective amount of] a siRNA inhibitor of NOX3, wherein NOX3 protein comprises or consists of the amino acid sequence of any one of SEQ ID NO:
Dependencies are inferred from the claim text.